Physician profile
Mark Clifford Schultz
NPI 1568411189
$1,286.30
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,056 · 2020: $230.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $230.25 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $185.81 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $143.37 | 2019-2020 | |
| Ucb, INC. | $108.20 | 2019 | |
| Amgen INC. | $80.12 | 2019 | |
| Greenwich Biosciences, INC. | $70.29 | 2019 | |
| Emd Serono, INC. | $64.92 | 2019-2020 | |
| Genzyme Corporation | $64.65 | 2019 | |
| Biogen, INC. | $48.11 | 2019-2020 | |
| Allergan, INC. | $46.12 | 2019-2020 | |
| Assertio Therapeutics, INC. | $26.77 | 2019 | |
| Mallinckrodt Enterprises LLC | $25.68 | 2019 | |
| Promius Pharma LLC | $24.67 | 2019 | |
| Lilly USA, LLC | $22.71 | 2019 | |
| Eisai INC. | $22.49 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Portola Pharmaceuticals, LLC | $20.42 | 2019 | |
| Abbott Laboratories | $18.90 | 2019 | |
| Adamas Pharmaceuticals, INC. | $18.59 | 2019 | |
| Acorda Therapeutics, INC | $18.41 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.76 | 2020 | |
| Alnylam Pharmaceuticals INC. | $15.42 | 2019 | |
| Janssen Biotech, INC. | $12.64 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.